Rami Komrojki

Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS

K. Do, H. Kantarjian, G. Garcia-Manero, 2022, NEJM Evidence.

Interrogation of molecular profiles can help in differentiating between MDS and AML with MDS-related changes

E. Padron, A. Szabo, D. Sallman, 2020, Leukemia & lymphoma.